<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608699</url>
  </required_header>
  <id_info>
    <org_study_id>HMA111316</org_study_id>
    <nct_id>NCT00608699</nct_id>
  </id_info>
  <brief_title>A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers</brief_title>
  <official_title>A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin
      are co-administered as single doses to HVTs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of reported flushing - visual analogue scale; self reported assessment of flushing</measure>
    <time_frame>up to 8 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of GSK256073A and immediate release niacin</measure>
    <time_frame>up to 36 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard and Secondary pharmacokinetic endpoints of interest</measure>
    <time_frame>up to 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response</measure>
    <time_frame>up to 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Dyslipidaemias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256073A tablets + IR niacin tablets</intervention_name>
    <description>single dosing for 4 to 5 sessions</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males between 18 and 55 years of age, inclusive.

          -  Healthy subjects

          -  Body weight &gt; 50 kg (110 pounds) and body mass index (BMI) between 19 and 31 where:

          -  Subjects with QTc &lt; 450 msec at screening

        Exclusion Criteria:

          -  History of significant cardiac arrhythmias

          -  Active peptic ulcer disease (PUD) and/or history of PUD

          -  History of gout and/or hyperuricemia

          -  History of Gilbert's syndrome

          -  History of recurrent indigestion, stomach upset or diarrhea

          -  History of other than rare (once yearly or less) flushing

          -  Recurrent skin rash or psoriasis

          -  History of kidney stones
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flushing</keyword>
  <keyword>GSK256073A,</keyword>
  <keyword>Dose Escalation,</keyword>
  <keyword>Immediate Release Niacin,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

